NSAID induced gastrointestinal mucosal lesions
Conditions
Interventions
Famotidine 20 mg/day b.i.d. and loxoprofen 180 mg/day t.i.d for 2 weeks by oral administration
Famotidine 20 mg/day b.i.d. and etodolac 400 mg/day b.i.d for 2 weeks by oral administration
Famotidine
Sponsors
Second Department of Internal Medicine, Osaka Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Healthy adults who are 20 years or older, and less than 80 years of age at the time of obtaining informed consent 2) Subjects from whom fully informed written consent based on their full understanding and their own voluntary will was obtained at the commencement of this study
Exclusion criteria
Exclusion criteria: 1) Subjects who have active peptic ulcer or gastrointestinal bleeding and need endoscopic treatment immediately 2) Subjects with significant hepatic disease, renal disease, heart disease or respiratory disease 3) Subjects with a history of gastrointestinal surgery other than appendectomy 4) Subjects orally taking or planning to orally take drug other than loxoprofen, etodolac, celecoxib or famotidine 5) Subjects with alcohol or chemical dependencies 6) Subjects with a history of intestinal obstruction, or person with suspected gastrointestinal obstruction on other tests 7)Subjects who cannot agree that surgery may be required if capsule endoscope retained in the body 8) Subjects whom otherwise the investigator determined ineligible as the subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The numbers of small intestinal mucosal breaks evaluated by capsule endoscopy | — |
Countries
Japan
Contacts
Public ContactEiji Umegaki
Osaka Medical College Second Department of Internal Medicine
Outcome results
None listed